- Home
- Publications
- Publication Search
- Publication Details
Title
Deucravacitinib: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 82, Issue 17, Pages 1671-1679
Publisher
Springer Science and Business Media LLC
Online
2022-11-20
DOI
10.1007/s40265-022-01796-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DOP42 Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately-to-severely active Ulcerative Colitis: 12-week results from the Phase 2 LATTICE-UC study
- (2022) S Danese et al. Journal of Crohns & Colitis
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Deucravacitinib for the Treatment of Psoriatic Disease
- (2022) Ana Maria Lé et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
- (2022) R. B. Warren et al. ANNALS OF THE RHEUMATIC DISEASES
- LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
- (2022) E. Morand et al. ANNALS OF THE RHEUMATIC DISEASES
- POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
- (2022) R. B. Warren et al. ANNALS OF THE RHEUMATIC DISEASES
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial
- (2022) Bruce Strober et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
- (2021) A. Armstrong et al. ANNALS OF THE RHEUMATIC DISEASES
- Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
- (2021) Anjaneya Chimalakonda et al. Dermatology and Therapy
- Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
- (2021) Ian M. Catlett et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
- (2020) Miguel Nogueira et al. DRUGS
- 349 - BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2, Blocks Il-12, IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease
- (2018) Jenny H. Xie et al. GASTROENTEROLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now